Epidermolysis Bullosa Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene
Condition: Dystrophic Epidermolysis Bullosa Interventions: Drug: PTW-002 10 mg/g gel; Drug: Placebo Sponsor: Phoenicis Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 6, 2022 Category: Research Source Type: clinical trials
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)
Condition: Epidermolysis Bullosa Interventions: Drug: allo-APZ2-OTS; Drug: Placebo Sponsor: RHEACELL GmbH & Co. KG Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2022 Category: Research Source Type: clinical trials
